A phase II trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701

Rituximab combined with chemotherapy has improved the survival of previously untreated patients with follicular lymphoma (FL). Nevertheless, many patients neither want nor can tolerate chemotherapy, leading to interest in biological approaches. Epratuzumab is a humanized anti-CD22 monoclonal antibod...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Grant, Barbara W., Jung, Sin-Ho, Johnson, Jeffrey L., Kostakoglu, Lale, His, Eric, Byrd, John C., Jones, Jeffrey, Leonard, John P., Martin, S. Eric, Cheson, Bruce D.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2013
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3828050/
https://ncbi.nlm.nih.gov/pubmed/23922187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28299
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन